Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

Controlled trial of topical R-salbutamol in discoid lupus erythematosus

An 8-week, randomized, multicenter, double-blind, placebo-controlled phase III trial of topical R-salbutamol 0.5% evaluated its efficacy and safety in 37 patients with discoid lupus erythematosus (DLE). The active cream or placebo-vehicle were applied b.i.d. to the lesions. A modified Localized Cutaneous Lupus Erythematosus Area and Severity Index (LCLASI) score was used to assess erythema, scaling/hypertrophy, dyspigmentation, scarring/atrophy/panniculitis and induration. A composite score of the LCLASI was used as the primary endpoint after 8 weeks, based on the area under the curve (AUC) of improvement. The mean AUC of improvement of the LCLASI was significantly better for R-salbutamol (versus placebo) for scaling/hypertrophy (P = 0.0262), pain (P = 0.0238) and itching (P = 0.0135). ...